Submit Manuscript  

Article Details


Modulatory nano/micro effects of diabetes development on pharmacology of primary and secondary bile acids concentrations

Author(s):

Armin Mooranian, Nassim Zamani, Ryu Takechi, Giuseppe Luna, Momir Mikov, Svetlana Goločorbin-Kon, Bozica Kovacevic, Frank Arfuso and Hani Al-Salami*  

Abstract:


Background: Recent studies have suggested that hyperglycaemia influences the bile acid profile and concentrations of secondary bile acids in the gut.

Introduction: This study aimed to measure changes in the bile acid profile in gut, tissues, and faeces in Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D).

Method: T1D and T2D were established in a mouse model. Twenty-one seven-weeks old balb/c mice were randomly divided into three equal groups, healthy, T1D and T2D. Blood, tissue, urine and faeces samples were collected for bile acid measurements.

Results: Compared with healthy mice, T1D and T2D mice showed lower levels of the primary bile acid chenodeoxycholic acid in the plasma, intestine, and brain, and higher levels of the secondary bile acid lithocholic acid in the plasma and pancreas. Levels of the bile acid ursodeoxycholic acid were undetected in healthy mice but were elevated in T1D and T2D mice.

Conclusion: Bile acid profiles in other organs were variably influenced by T1D and T2D development, which suggests similarity in effects of T1D and T2D on the bile acid profile, but these effects were not always consistent among all organs, possibly since feedback mechanisms controlling enterohepatic recirculation and bile acid profiles and biotransformation are different in T1D and T2D.

Keywords:

Type 1 diabetes, Type 2 diabetes, lithocholic acid, secondary bile acids, chenodeoxycholic acid, balb/c mice

Affiliation:

Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, School of Public Health, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia



Full Text Inquiry